Selected Media

  • Machine learning to improve serious illness communication study. Coverage of our project to use machine learning to improve serious illness communication. Links: Penn Medicine, ASCO Post, AJMC, Daily Pennsylvanian, Becker’s Hospital Review, LDI

  • The FDA Accelerated Approval Program. Coverage of our work on physician use of oncology drugs that receive accelerated approval. Nature, ESMO, Regulatory Focus, Medpage Today, Cancer Therapy Advisor, Oncology Data Advisor, Biospace

  • Reimbursement of AI in medicine. Coverage of a line of work exploring how we pay for artificial intelligence in medicine. Links: LDI.

  • Alternative payment models in oncology. Coverage of recent work exploring challenges in oncology APMs, and highlighting unique academic-community oncology partnerships to spur innovation in cancer care delivery. Links: AJMC

  • Default EHR Orders to Increase Palliative Care Referrals In a Large Community Oncology Network. Coverage of novel partnership between Penn and Tennessee Oncology to merge predictive analytics and behavioral economics to improve value-based cancer. Links: OBR, Penn

  • Immunotherapy use in real-world patients. Coverage of JAMA Oncology study investigating checkpoint inhibitor use and outcomes in trial-ineligible patients. Links: Cure, ABC Radio, Conquer Cancer Foundation, Helio, ASCO Post, Penn

  • Racial disparities in prostate cancer. Coverage of JAMA Network Open study studying Black-White differences in treatment effectiveness. Links: Urology Times, Renal & Urology News.

  • Examining unfairness in AI. Coverage of large VA study to examine algorithmic unfairness in VA algorithms. Links: VA.

  • Response to COVID vaccine in patients with cancer. Coverage of JAMA Oncology editorial on vaccine effectiveness in patients with cancer. Links: Science, MedPage Today

  • AI and Medical Liablity. Coverage on Milbank Quarterly article on AI and medical liability. Links: LDI

  • FDA and immunotherapy label changes. Coverage of JAMA article examining impact of FDA label restriction on immunotherapy. Link: Cancer Letter.